TRP_1170x120_3-8-19

Mylan Pharmaceuticals

Launch of generic Lialda expands Mylan’s gastroenterology product offering

Launch of generic Lialda expands Mylan’s gastroenterology product offering

PITTSBURGH — Mylan N.V. announced the U.S. launch of mesalamine delayed-release tablets USP, 1.2 g, a generic version of Shire’s Lialda Delayed-Release Tablets. Mylan Pharmaceuticals received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the induction of remission in patients with active,

Mylan and WVU join forces to inspire STEM-CARE

Mylan and WVU join forces to inspire STEM-CARE

MORGANTOWN, W.Va. — Global pharmaceutical company Mylan and West Virginia University (WVU) today announced a 10-year collaboration, supported by a $5 million charitable contribution from Mylan, to develop and implement a program that will expose children across West Virginia to STEM (Science, Technology, Engineering and Math) and challenge traditional thinking about how STEM skills can be

Mylan adds to growing women’s healthcare portfolio

Mylan adds to growing women’s healthcare portfolio

HERTFORDSHIRE, England and PITTSBURGH — Global pharmaceutical company Mylan N.V. announced the U.S. launch of Drospirenone and Ethinyl Estradiol tablets USP, 3 mg/0.02 mg, a generic version of Bayer’s Yaz tablets. Mylan Pharmaceuticals received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which

Mylan to partner with Mapi Pharma on new MS drug

Mylan to partner with Mapi Pharma on new MS drug

HERTFORDSHIRE, England and PITTSBURGH and NESS ZIONA, Israel — Mylan N.V. and Mapi Pharma Ltd. announced that the two companies will team on the development and commercialization of GA Depot, a long-acting Glatiramer Acetate product. Mylan is acquiring global marketing rights to the product. GA Depot is a proposed once-monthly injection for the treatment of

Suit accuses six generic drug makers of price fixing

Suit accuses six generic drug makers of price fixing

HARTFORD, Conn. — Twenty states have accused six generic drug manufacturers of price ­fixing. The states’ attorneys general also said their lawsuit, filed in federal court here, may be just the start of a much broader legal action. The suit charges that the drug makers, led by New Jersey-based Heritage Pharmaceuticals, conspired to artificially elevate